Literature DB >> 1372189

Internalization and intracellular fate of anti-CD5 monoclonal antibody and anti-CD5 ricin A-chain immunotoxin in human leukemic T cells.

S Ravel1, M Colombatti, P Casellas.   

Abstract

We have investigated the entry and subsequent intracellular fate of T101 monoclonal antibody (MoAb) and T101-ricin A-chain (RTA) immunotoxin (IT) directed against the CD5 antigen (Ag) expressed on human leukemic CEM cells. We provide direct evidence for the internalization of T101 MoAb and the corresponding IT. Both the MoAb and IT were internalized at a relatively low rate. This slow internalization process could be related to the partial recycling of the MoAb/Ag or IT/Ag complexes. Analysis of the internalized molecules showed that their molecular weight was only partially altered after internalization and that no free A-chain could be found inside the cells, indicating that lysosomal degradation and cleavage of disulfide-linked conjugates is a quantitatively minor phenomenon compared with the localization of internalized anti-CD5 ITs in an endosomo-Golgi compartment, followed by their recycling to the cell surface. We believe that this is the major factor explaining the low efficacy of anti-CD5 IT when assayed in the absence of potentiating substances. Finally, we showed that the presence of ammonium chloride and monensin, which both dramatically enhance the kinetics of IT activity, did not affect the rate of internalization or the intracellular localization of the conjugate, suggesting that these activators could act at the postendocytotic level on a limited number of IT molecules.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372189

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Different cytotoxic activity and intracellular fate of an anti-CD5-momordin immunotoxin in normal compared to tumour cells.

Authors:  G Porro; P Lento; F Marcucci; G Gromo; D Modena
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

2.  In vitro evaluation of Pyrularia thionin-anti-CD5 immunotoxin.

Authors:  S E Gasanov; E D Rael; N E Gasanov; L P Vernon
Journal:  Cancer Immunol Immunother       Date:  1995-08       Impact factor: 6.968

Review 3.  Receptor-directed therapy of T-cell leukemias and lymphomas.

Authors:  John C Morris; Thomas A Waldmann; John E Janik
Journal:  J Immunotoxicol       Date:  2008-04       Impact factor: 3.000

Review 4.  Bacterial Toxins for Cancer Therapy.

Authors:  Nour-Imene Zahaf; Gudula Schmidt
Journal:  Toxins (Basel)       Date:  2017-07-28       Impact factor: 4.546

Review 5.  Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies.

Authors:  Hendrik Fuchs; Nicole Niesler; Alexandra Trautner; Simko Sama; Gerold Jerz; Hossein Panjideh; Alexander Weng
Journal:  Biomedicines       Date:  2017-03-29

6.  A Flow Cytometric Method to Quantify the Endosomal Escape of a Protein Toxin to the Cytosol of Target Cells.

Authors:  Harrison J Wensley; David A Johnston; Wendy S Smith; Suzanne E Holmes; Sopsamorn U Flavell; David J Flavell
Journal:  Pharm Res       Date:  2019-12-23       Impact factor: 4.200

7.  The Role of Cholesterol on Triterpenoid Saponin-Induced Endolysosomal Escape of a Saporin-Based Immunotoxin.

Authors:  Wendy S Smith; David A Johnston; Harrison J Wensley; Suzanne E Holmes; Sopsamorn U Flavell; David J Flavell
Journal:  Int J Mol Sci       Date:  2020-11-19       Impact factor: 5.923

Review 8.  Augmenting the Efficacy of Immunotoxins and Other Targeted Protein Toxins by Endosomal Escape Enhancers.

Authors:  Hendrik Fuchs; Alexander Weng; Roger Gilabert-Oriol
Journal:  Toxins (Basel)       Date:  2016-07-01       Impact factor: 4.546

Review 9.  The expansion of targetable biomarkers for CAR T cell therapy.

Authors:  Michelle H Townsend; Gajendra Shrestha; Richard A Robison; Kim L O'Neill
Journal:  J Exp Clin Cancer Res       Date:  2018-07-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.